Published in Neuropsychopharmacology on March 22, 2017
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc (2006) 3.71
The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process (2011) 2.74
Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc (2007) 2.63
T-maze alternation in the rodent. Nat Protoc (2006) 2.38
Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci (2011) 2.31
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) (2004) 2.06
Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun (2007) 1.86
Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry (2005) 1.85
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev (2009) 1.74
Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry (2006) 1.69
Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res (2011) 1.62
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr (2008) 1.61
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry (2013) 1.30
Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist (2003) 1.28
Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.26
Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry (2009) 1.22
The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry (2014) 1.14
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull (2010) 1.13
Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther (2011) 1.12
Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull (2008) 1.06
Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol (2011) 1.05
Cortical circuit dysfunction and cognitive deficits in schizophrenia--implications for preemptive interventions. Eur J Neurosci (2012) 1.04
Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol (2014) 1.04
Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci (2004) 1.04
Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res (2006) 1.03
To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology (2011) 1.01
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) (2011) 1.00
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol (2009) 0.99
Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. Schizophr Res (2012) 0.97
Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci Res (2009) 0.96
Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite (2006) 0.93
Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience (2011) 0.92
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther (2009) 0.92
A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res (2013) 0.90
Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain (2012) 0.88
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res (2010) 0.88
Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav Brain Res (2011) 0.88
Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs (2013) 0.87
Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox Res (2014) 0.87
Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. PLoS One (2013) 0.86
Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice. Pharmacol Biochem Behav (2011) 0.85
Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol (2014) 0.85
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats. J Psychopharmacol (2015) 0.84
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One (2012) 0.84
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. J Psychopharmacol (2012) 0.84
Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Neurobiol Dis (2012) 0.83
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One (2012) 0.83
Prenatal infection affects the neuronal architecture and cognitive function in adult mice. Dev Neurosci (2014) 0.83
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res (2015) 0.83
Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res (2010) 0.83
Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2013) 0.82
Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model. Int J Neuropsychopharmacol (2015) 0.82
Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice. Psychopharmacology (Berl) (2014) 0.82
Deficient maternal care resulting from immunological stress during pregnancy is associated with a sex-dependent enhancement of conditioned fear in the offspring. J Neurodev Disord (2008) 0.82
Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid. Psychiatry Res (2014) 0.82
Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol (2013) 0.82
Maternal immune activation induces GAD1 and GAD2 promoter remodeling in the offspring prefrontal cortex. Epigenetics (2015) 0.82
Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur J Pharmacol (2012) 0.82
Behavioural deficits associated with maternal immune activation in the rat model of schizophrenia. Behav Brain Res (2011) 0.81
Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway. J Neurosci (2016) 0.81
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.81
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats. Behav Brain Res (2011) 0.81
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. Behav Brain Res (2007) 0.81
Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behav Brain Res (2007) 0.80
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr (2010) 0.80
Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates. Biol Psychiatry (2016) 0.80
Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology (Berl) (2011) 0.78
Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis (2014) 0.78
Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors. Behav Pharmacol (2015) 0.77
Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic? Schizophr Res (2009) 0.77
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry (2016) 0.77
Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience (2015) 0.77
Prenatal exposure to the viral mimetic poly I:C alters fetal brain cytokine expression and postnatal behaviour. Dev Neurosci (2014) 0.77
MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behav Pharmacol (2015) 0.77
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.76
Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia. Schizophr Res (2016) 0.76
The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats. Pharmacol Rep (2015) 0.76
Maternal Immune Activation Disrupts Dopamine System in the Offspring. Int J Neuropsychopharmacol (2016) 0.76
Sub-chronic Antipsychotic Drug Administration Reverses the Expression of Neuregulin 1 and ErbB4 in a Cultured MK801-Induced Mouse Primary Hippocampal Neuron or a Neurodevelopmental Schizophrenia Model. Neurochem Res (2016) 0.76
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci Biobehav Rev (2016) 0.76
An automated maze task for assessing hippocampus-sensitive memory in mice. Behav Brain Res (2013) 0.76
Prenatal immune activation in mice blocks the effects of environmental enrichment on exploratory behavior and microglia density. Prog Neuropsychopharmacol Biol Psychiatry (2016) 0.75
Ginsenoside Rb1 improves leptin sensitivity in the prefrontal cortex in obese mice. CNS Neurosci Ther (2017) 0.75
Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. Sci Rep (2017) 0.75
Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats. Sci Rep (2017) 0.75
Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity. Obes Rev (2017) 0.75
Luteolin, a natural flavonoid, inhibits methylglyoxal induced apoptosis via the mTOR/4E-BP1 signaling pathway. Sci Rep (2017) 0.75
Dietary teasaponin ameliorates alteration of gut microbiota and cognitive decline in diet-induced obese mice. Sci Rep (2017) 0.75